The Cellularity Yield of Three Different 22-gauge FNA Needles
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01916421
Recruitment Status :
First Posted : August 5, 2013
Last Update Posted : May 17, 2017
Texas Tech University Health Sciences Center, El Paso
Information provided by (Responsible Party):
Mohamed O Othman, Texas Tech University Health Sciences Center, El Paso
Obtaining a sample from a lesion in the gastrointestinal tract by endoscopic ultrasound (a flexible tube with a camera and small ultrasound machine at its end )requires the use of a needle for taking the sample from the lesion or what we call "Fine needle aspiration (FNA)". Currently, FNA is done by three commercially available needles. These needles are used routinely in our institution for FNA. The data regarding the safety and the successfulness of any of these needles are lacking. We sought to compare all three commercially available needles in a prospective manner.
Condition or disease
Pancreatic or Peripancreatic LesionsLesions in the Esophagus, Stomach, Duodenum or RectumMediastinal ( Chest) MassesEnlarged Lymph Nodes
Procedure: Endoscopic Ultrasound Fine Needle Aspiration (EUS-FNA)
The following are being done only for research purposes; prior to performing the FNA, The patient will be randomized to one of the three commercially available FNA needles. At this time, all needles are considered equivalent and there is no medical necessity to pick one over another. The sample obtained by the needle will be assigned a quality score based on certain parameters of the sample such as the abundance of diagnostic cells and the presence of blood. We are going to collect certain information about your procedure such as the complications of the procedure, number of needle passes and final diagnosis.
1. Compare the overall diagnostic accuracy of the three commercially available 22 gauge EUS needles [ Time Frame: 2 days after the procedure ]
Cellularity score will be assessed by the cytopathologist using the scoring system from 0 to 10 score. This scoring system evaluate the amount of blood, malignant cells and contaminant cells. The system is a modified form Mair et al study. " Mair S, Dunbar F, Becker PJ, Du Plessis W. Fine needle cytology--is aspiration suction necessary? A study of 100 masses in various sites. Acta cytologica 1989;33:809-13."
Secondary Outcome Measures :
Compare the complication rate between the three commercially available 22 gauge EUS needles. [ Time Frame: up to 1 month after the procedure ]
The patient will be contacted after the procedure by one week to review any procedure complications. The patient's medical records may be reviewed for up to 6 months after the procedure to review the surgical resection results or the long-term follow-up results. If the patient receives his further care in another hospital, the patient will be contacted by phone for follow-up for a maximum period of 6 months.
Compare the number of FNA needles passes required to reach the diagnosis. [ Time Frame: During the procedure ( 30 -45 minutes) ]
The number of passes required to reach the diagnosis
Compare the technical success of the three commercially available 22 gauge EUS needles [ Time Frame: During the procedure ( 30-45 minutes) ]
The ability of the needle to perform the intended purpose of the procedure ( reach the lesion and obtain sufficient tissues)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 88 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Adult patients (18-88) who are undergoing EUS FNA of pancreatic or peripancreatic lesions
Adult patients (18-88) who are undergoing EUS FNA of submucosal masses in the esophagus, stomach, duodenum or rectum
Adult patients (18-88) who are undergoing EUS FNA of mediastinal masses.
Adult patients (18-88) who are undergoing EUS FNA of enlarged lymph nodes
Patients younger than 18 yrs old or older than 88 yrs.